Elisabet Manasanch, MD MD Anderson Cancer Center Interview Date: April 26, 2017 

MGUS and smoldering myeloma are precursor conditions to multiple myeloma. For those with the early markers, who will progress and who will not? Dr. Elisbet Manasanch at MD Anderson Cancer Center is using myeloma genetics testing to help determine answers to this important question. Dr. Manasanch describes a study she has open to test MGUS and smoldering myeloma patients using a test called the GEP-70, a gene expression profile test and observe the way that their disease potentially changes over time. The answers to this study will help myeloma specialists know how to segment patients into different groups and identify who may benefit from early treatment. She also describes a study open at MD Anderson for high-risk smoldering myeloma patients using a monoclonal antibody called Isatuximab.  To find the two clinical trials discussed in this show, click here: Isatuximab Clinical Trial for High-Risk Smoldering Myeloma   MGUS and Smoldering Myeloma Genomics Study To find all clinical trials at MD Anderson Cancer Center, click here: MD Anderson Myeloma Clinical Trials Dr. Elisabet Manasanch on Myeloma Crowd Radio